Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 359

Sort by

Sort Order Select

Journal Articles

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Blood (2025) 146 (21): 2608–2611.

https://doi.org/10.1182/blood.2025029391

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia

Roberta S. Azevedo, Elias Jabbour, Hagop M Kantarjian, Sravanthi Lavu, Sanam Loghavi, Nitin Jain, Koji Sasaki, Rebecca Garris, Koichi Takahashi, Farhad Ravandi, Nicholas J. Short

Blood blood.2025030498.

https://doi.org/10.1182/blood.2025030498

Published: 2025

Includes: Supplemental data

Journal Articles

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Blood (2025) 146 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2025-3399

Published: 2025

Journal Articles

Clinical and biological correlates of blast-transformed chronic myelomonocytic leukemia (CMML): A multicenter study of 493 paired cases at chronic phase and at blast transformation

Blood (2025) 146 (Supplement 1): 2081.

https://doi.org/10.1182/blood-2025-2081

Published: 2025

Journal Articles

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)

Blood (2025) 146 (Supplement 1): 3775.

https://doi.org/10.1182/blood-2025-3775

Published: 2025

Journal Articles

Clinical characteristics, demographics, and survival outcomes in newly diagnosed CUX1-mutated Acute Myeloid Leukemia

Michelle Nwachukwu, Farhad Ravandi, Sanam Loghavi, Gautam Borthakur, Tapan Kadia, Courtney DiNardo, Nicholas Short, Elias Jabbour, Guillermo Montalban-Bravo, Alexandre Bazinet, Alex Bataller, Kelly Chien, Danielle Hammond, Mahesh Swaminathan, Wei-Ying Jen, Ian Bouligny, Naval Daver, Guillermo Garcia-Manero, Koji Sasaki

Blood (2025) 146 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2025-1620

Published: 2025

Journal Articles

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)

Blood (2025) 146 (Supplement 1): 906.

https://doi.org/10.1182/blood-2025-906

Published: 2025

Journal Articles

A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician's choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5228.

https://doi.org/10.1182/blood-2025-5228

Published: 2025

Journal Articles

Clinical outcomes of patients with IDH1/IDH2-mutated clonal hematopoiesis: A single-center retrospective study

Fnu Amritpal Singh, Koji Sasaki, Sanam Loghavi, William D. Marrero, Guillermo Montalban-Bravo, Koichi Takahashi, Hagop Kantarjian, Guillermo Garcia-Manero, Courtney DiNardo, Kelly Chien

Blood (2025) 146 (Supplement 1): 6710.

https://doi.org/10.1182/blood-2025-6710

Published: 2025

Journal Articles

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Mahesh Swaminathan, Nitin Jain, Alexandra Lovell, Ashley Dinh, Alessandra Ferrajoli, Jan Burger, Musa Yilmaz, Tapan Kadia, Lucia Masarova, Yesid Alvarado Valero, Prithviraj Bose, Farhad Ravandi, Koji Sasaki, Wei Qiao, Zhouxuan Li, Naveen Garg, Michael Keating, William Wierda

Blood (2025) 146 (Supplement 1): 5687.

https://doi.org/10.1182/blood-2025-5687

Published: 2025

Journal Articles

Post-transplant maintenance with revumenib in children with HOX-driven AML

Blood (2025) 146 (Supplement 1): 3461.

https://doi.org/10.1182/blood-2025-3461

Published: 2025

Journal Articles

Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia

Hannah Goulart, Hagop Kantarjian, Nitin Jain, Jayastu Senapati, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Koji Sasaki, Fadi Haddad, Guillermo Garcia-Manero, Rebecca Garris, Nicholas Short

Blood (2025) 146 (Supplement 1): 5131.

https://doi.org/10.1182/blood-2025-5131

Published: 2025

Journal Articles

Area deprivation index does not influence survival in patients with lower-risk myelodysplastic syndromes at a major cancer center

Mahesh Swaminathan, Alexandre Bazinet, Koji Sasaki, Dan Fox, James Hill, Alex Bataller, Kelly Chien, Guillermo Montalban-Bravo, Danielle Hammond, Michelle Hildebrandt, Ian Bouligny, Wei-Ying Jen, Tapan Kadia, Koichi Takahashi, Courtney DiNardo, Elias Jabbour, Naval Daver, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 6407.

https://doi.org/10.1182/blood-2025-6407

Published: 2025

Journal Articles

Post-transplant bendamustine (PT-BEN) with or without cyclophosphamide for gvhd prophylaxis after haplo-identical or matched unrelated donor transplants: A phase I/II trial

Issa Khouri, Susan Wu, Fadi Haddad, Denai Milton, Tapan Kadia, Nicholas Short, Koji Sasaki, Jin Im, David Marin, Rohtesh Mehta, Gabriela Rondon, Hind Rafei, Jeremy Ramdial, Guillermo Garcia-Manero, Dan Li, Alison Gulbis, Bouthaina Dabaja, Elias Jabbour, Qing Ma

Blood (2025) 146 (Supplement 1): 6022.

https://doi.org/10.1182/blood-2025-6022

Published: 2025

Journal Articles

Asciminib for newly diagnosed chronic myeloid leukemia: Results from A phase II trial

Fadi Haddad, Elias Jabbour, Ghayas Issa, Koji Sasaki, Rita Khouri, Alex Bataller, Jayastu Senapati, Tapan Kadia, Guillermo Montalban-Bravo, Naveen Pemmaraju, Anwesha Ray, Sara Dellasala, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 5565.

https://doi.org/10.1182/blood-2025-5565

Published: 2025

Journal Articles

Luspatercept response predictors in lower-risk myelodysplastic syndrome

Vanthana Bharathi, Ian Bouligny, Emmanuel Almanza, Alex Bataller, Alexandre Bazinet, Wei-Ying Jen, Niranjan Khaire, Koji Sasaki, Danielle Hammond, Courtney DiNardo, Gautam Borthakur, Tapan Kadia, Naval Daver, Ghayas Issa, Musa Yilmaz, Kelly Chien, Guillermo Montalban-Bravo, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5648.

https://doi.org/10.1182/blood-2025-5648

Published: 2025

Journal Articles

Evaluating the impact of stem cell transplantation in myelodysplastic syndrome using machine learning and comparative modeling

Ziyi Li, Kelly Chien, Yue Lyu, Koji Sasaki, Ian Bouligny, Yue Wei, Guillermo Montalban-Bravo, Sanam Loghavi, Alex Bataller, Uday Popat, Hagop Kantarjian, Alexandre Bazinet, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5644.

https://doi.org/10.1182/blood-2025-5644

Published: 2025

Journal Articles

Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes

Alex Bataller, Alexandre Bazinet, Guillermo Montalban-Bravo, Kelly Chien, Danielle Hammond, Ian Bouligny, Jayastu Senapati, Koji Sasaki, Ghayas Issa, Nicholas Short, Tapan Kadia, Rashmi Kanagal-Shamanna, Sanam Loghavi, Guilin Tang, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5641.

https://doi.org/10.1182/blood-2025-5641

Published: 2025

Journal Articles

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

Blood (2025) 146 (Supplement 1): 3867.

https://doi.org/10.1182/blood-2025-3867

Published: 2025

Journal Articles

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Blood (2025) 146 (Supplement 1): 3857.

https://doi.org/10.1182/blood-2025-3857

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Clinical and biological correlates of blast-transformed chronic myelomonocytic leukemia (CMML): A multicenter study of 493 paired cases at chronic phase and at blast transformation

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)

Clinical characteristics, demographics, and survival outcomes in newly diagnosed CUX1-mutated Acute Myeloid Leukemia

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)

A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician's choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in Acute Myeloid Leukemia

Clinical outcomes of patients with IDH1/IDH2-mutated clonal hematopoiesis: A single-center retrospective study

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Post-transplant maintenance with revumenib in children with HOX-driven AML

Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia

Area deprivation index does not influence survival in patients with lower-risk myelodysplastic syndromes at a major cancer center

Post-transplant bendamustine (PT-BEN) with or without cyclophosphamide for gvhd prophylaxis after haplo-identical or matched unrelated donor transplants: A phase I/II trial

Asciminib for newly diagnosed chronic myeloid leukemia: Results from A phase II trial

Luspatercept response predictors in lower-risk myelodysplastic syndrome

Evaluating the impact of stem cell transplantation in myelodysplastic syndrome using machine learning and comparative modeling

Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only